"With good line guard use compliance and no other practice changes occurring simultaneously, findings suggest a line guard is a promising addition to CLABSI prevention bundles, especially for patients at highest risk of external contamination to their lines" Lulgjuraj et al (2025).

Evaluation of a line guard for pediatric CLABSI prevention

Abstract:

Highlights: Implementation of the line guard led to a significant decrease in central line-associated bloodstream infection (CLABSI) incidence Since implementing the line guard, the Pediatric Critical Care Unit (PCCU) is CLABSI-free Consistent audits showed CLABSI rates improving over time.

Background: Clinicians strive for a central line-associated bloodstream infection (CLABSI)-free environment. Effective prevention strategies are crucial to reducing the burdens associated with these infections. The purpose of this study was to assess whether a line guard, a transparent line-to-line barrier against gross contamination, was effective in contributing to the reduction of pediatric CLABSIs.

Methods: A line guard was implemented into central venous access device (CVAD) practices for all inpatients at 1 children’s hospital. This pre-post intervention study assessed its effectiveness in CLABSI prevention, comparing retrospective surveillance records to postimplementation data.

Results: CLABSI rates throughout the hospital were significantly lower during the study period (P=0.0208), and since implementation of the line guard, the PCCU has been over 1 year CLABSI free (P=0.0189).

Conclusions: With good line guard use compliance and no other practice changes occurring simultaneously, findings suggest a line guard is a promising addition to CLABSI prevention bundles, especially for patients at highest risk of external contamination to their lines.


Reference:

Lulgjuraj D, Buckenmyer T, Biel N. Evaluation of a line guard for pediatric central line-associated bloodstream infection prevention: a pre-post intervention study. Br J Nurs. 2025 Nov 20;34(21):S20-S25. doi: 10.12968/bjon.2025.0545. PMID: 41288029.